SEC Form 4 · accession 0001214659-18-004985
NEXIEN BIOPHARMA, INC. · NXEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alain D Bankier
Officer — Chief Executive Officer · Director
Period of report
Jul 25, 2018
Accepted (ET)
Jul 26, 2018 · 11:38 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001625288
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 2,256,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option - right to buyF2,F1 | $0.54 | Jul 25, 2018 | A | 840,000 | A | Jul 25, 2018 | Jul 25, 2025 | Common Stock | 840,000 | 840,000 | D |
| Stock option - right to buyF2,F3 | $0.54 | Jul 25, 2018 | A | 100,000 | A | Jul 25, 2018 | Jul 25, 2025 | Common Stock | 100,000 | 100,000 | D |
| Class C Warrants (right to buy) | $0.50 | holding | — | — | — | Nov 29, 2017 | Jul 27, 2018 | Common Stock | 28,000 | 28,000 | D |
Explanation of responses
- F170,000 options vested immediately, with the remainder vesting monthly over the next 11 months beginning August 1, 2018.
- F2Granted under the Company's 2018 Equity Incentive Plan.
- F325,000 options vested immediately, with the remainder vesting quarterly over the next 6 quarters beginning with the quarter ending September 30, 2018.